日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Dual Aptamers-Based SETDB1 PROTACs as Effective Anti-Tumor Strategies for Breast Cancer.

基于双适体的SETDB1 PROTAC作为乳腺癌的有效抗肿瘤策略。

Guo Yanxuan, Lv Yingge, Huang Shuyu, Liu Chang, Ouyang Yan, Lan Bei, Xuan Chenghao

ATF7IP inhibits Sorafenib-induced ferroptosis in hepatocellular carcinoma cells by inhibiting CYB5R2 transcription and stabilizing PARK7 protein.

ATF7IP 通过抑制 CYB5R2 转录和稳定 PARK7 蛋白来抑制索拉非尼诱导的肝细胞癌细胞铁死亡

Su Yijie, Huang Sirui, Duan Yang, Zhang Liang, Feng Shengyun, Lv Yingge, Lan Bei, Xuan Chenghao

First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation

吉非替尼联合贝伐珠单抗和化疗作为EGFR突变晚期非鳞状非小细胞肺癌的一线治疗方案

Xiong, Yanjuan; Wang, Lu; Zhang, Weihong; Meng, Yuan; Wang, Yang; Shen, Meng; Zhou, Li; Li, Runmei; Lv, Yingge; Wang, Shengguang; Ren, Xiubao; Liu, Liang

Establishment of an animal model of immune-related adverse events induced by immune checkpoint inhibitors

建立免疫检查点抑制剂诱发的免疫相关不良事件的动物模型

Meng, Yuan; Lv, Yingge; Shen, Meng; Yu, Wenwen; Liu, Yumeng; Liu, Ting; Liu, Gen; Ma, Shiya; Hui, Zhenzhen; Ren, Xiubao; Liu, Liang